๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Secukinumab

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our China, USA, UK and India registers that name Secukinumab as an intervention. Synced 24 Sep 2026
7Trials tracked
4Recruiting now
4Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Secukinumab is named as a drug or biological intervention in 7 clinical trials in our China, USA, UK and India trial registers, 4 of which are recruiting. Lead sponsors include Novartis Pharmaceuticals (4), Peking Union Medical College (1) and The Affiliated Hospital Of Guizhou Medical University (1). Registered phases: Phase 4, Phase 3 and Phase 1. Conditions studied include Hidradenitis Suppurativa (HS); Polymyalgia Rheumatica; Juvenile Psoriatic Arthritis.

Secukinumab also has an approved-drug profile on this site (FDA label data): Cosentyx (Secukinumab) →
01

Clinical trials of Secukinumab

7 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT04638647 Secukinumab Open Label Roll-over Extension Protocol (ClinicalTrials.gov ↗)
Autoimmunity, Inflammation
Phase 4 Recruiting Novartis Pharmaceuticals USA, India, China
NCT05303285 A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis (ClinicalTrials.gov ↗)
Ankylosing Spondylitis (AS)
Phase 4 Recruiting Tongji Hospital China
NCT07489573 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa (ClinicalTrials.gov ↗)
Hidradenitis Suppurativa (HS)
Phase 4 Recruiting Novartis Pharmaceuticals China
NCT06751238 Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). (ClinicalTrials.gov ↗)
Juvenile Psoriatic Arthritis
Phase 1 Recruiting Novartis Pharmaceuticals USA
NCT06833112 Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor ฮฑ (TNFฮฑ )Inhibitor for the Treatment of Ankylosing Spondylitis (ClinicalTrials.gov ↗)
Ankylosing Spondylitis
Phase 4 Not yet open The Affiliated Hospital Of Guizhou Medical University China
NCT07261072 Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS (ClinicalTrials.gov ↗)
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
Phase 4 Not yet open Peking Union Medical College China
NCT06331312 Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Polymyalgia Rheumatica
Phase 3 Active, closed Novartis Pharmaceuticals UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

8 conditions
Condition (as registered)Trials
Hidradenitis Suppurativa (HS)2
Polymyalgia Rheumatica1
Juvenile Psoriatic Arthritis1
Autoimmunity, Inflammation1
Hidradenitis Suppurativa (Acne Inversa)1
Secukinumab1
Ankylosing Spondylitis1
Ankylosing Spondylitis (AS)1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Novartis Pharmaceuticals4
Peking Union Medical College1
The Affiliated Hospital Of Guizhou Medical University1
Tongji Hospital1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Secukinumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Secukinumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.